Managing HCV infection in pediatric age group: Suggested recommendations

Saudi Journal of Gastroenterology

Volumn 16, Issue 3, 2010, Pages 230-235

  Danish, Fazal A ^a   Koul, Salman S ^b   Subhani, Fazal R ^c   Rabbani, Ahmed E ^d   Yasmin, Saeeda ^e  

^a PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^c HOLY FAMILY HOSPITAL   (Pakistan)

^d FOUNDATION UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^e Department of Neurosurgery   (Pakistan)

Author keywords

Antiviral therapy; children; chronic hepatitis C

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT;

CHILDHOOD DISEASE; DISEASE COURSE; DISEASE DURATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADOLESCENT; BIOPSY; BLOOD TRANSFUSION; CHILD; INFANT; LIVER FUNCTION TEST; NEWBORN; PAKISTAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRESCHOOL CHILD; RISK FACTOR; TRANSMISSION;

ADOLESCENT; ANTIVIRAL AGENTS; BIOPSY; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; LIVER FUNCTION TESTS; PAKISTAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 77954774460     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.65182     Document Type: Review

References (36)

1. Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J, et al. PSG consensus statement on the management of hepatitis C virus infection-2003. J Pak Med Assoc 2004;54:146-150
2. Jonas MM. Children with hepatitis C. Hepatology 2002;36:S173-8.
3. Davison SM, Kelly DA. Management strategies for hepatitis C virus infection in children. Paediatr Drugs 2008;10:357-365
4. Bortolotti F, Resti M, Giacchino R, Crivellaro C, Zancan L, Azzari C, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998;133:378-381
5. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900-1907
6. Hsu SC, Chang MH, Chen DS, Hsu HC, Lee CY. Non-A, non-B hepatitis in children: A clinical, histologic, and serologic study. J Med Virol 1991;35:1-6.
7. Bortolotti F, Vajro P, Cadrobbi P, Lepore L, Zancan L, Barbera C, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992;15:73-76
8. Bortolotti F, Jara P, Diaz C, Vajro P, Hierro L, Giacchino R, et al. Post transfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994;18:279-283
9. Bortolotti F, Resti M, Giacchino R, Azzari C, Gussetti N, Crivellaro C, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997;130:990-993
10. Kage M, Fujisawa T, Shiraki K, Tanaka T, Fujisawa T, Kimura A, et al. Pathology of chronic hepatitis C in children: Child Liver Study Group ofJapan. Hepatology 1997;26:771-775
11. Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416-1423 (Pubitemid 28493855)
12. Guido M, Rugge M, Jara P, Hierro L, Giacchino R, Larrauri J, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115:1525-1529 (Pubitemid 28546004)
13. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007;21:25C-34. (Pubitemid 47177083)
14. Danish FA. Current standards in the pharmacotherapy of chronic hepatitis C and local practices. Infect Dis J 2008;17:93-97
15. American Academy of Pediatrics, Committee on Infectious Diseases. 1997 Red book: report of the committee on infectious diseases. 24th ed. Elk Village, Ill.: American Academy of Pediatrics; 1997. p. 263.
16. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology 2002;36:973-977
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699
19. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-56.
20. Gonzalez-Peralta RP, Langham MR Jr, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009;48:630-635
21. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171
22. Gonzalez-Peralta R, Haber BA, Jonas M, Martin S, Lang T, Geffner M, et al. Interferon-alfa 2b in combination with ribavirin for the treatment of chronic hepatitis C in children. Hepatology 2002;36:311A.
23. Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-148
24. Palumbo E. Treatment for chronic hepatitis C in children: A review. Am J Ther 2009;16:446-450
25. Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics. Hepatology 2005;42:1010-1018
26. Jacobsen IM, Ahmed F, Russo MW, Brown RS, Lebovics E, Min A, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results. Gastroenterology 2003;124:A540.
27. Comanor L, Minor J, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139-147
28. Gottrand F, Michaud L, Guimber D, Ategbo S, Dubar G, Turck D, et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996;155:1031-1034
29. Bunn S, Kelly D, Murray KF, Shelton M, Olson A, Mieli-Vergani G, et al. Safetty, efficacy and pharmacokinetics of interferonalfa-2b and ribavirin in children with chronic hepatitis C. Hepatology 2000;32:350A.
30. Maddrey WC. Safetty of combination interferon alfa-2b/RBV therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19:67-75.
31. Mirza R, Memon I, Cheema HA, Ali S, Thobani S, Shah U. Recommendations for the treatment of chronic Hepatitis C infection in children. J Pak Med Assoc 2007;57:419-420 (Pubitemid 351251092)
32. Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Role of haematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol 2008;14:151-157
33. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206-212
34. Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safetty, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008;27:1081-1085
35. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-39.
36. Mast EE, Alter MJ. Hepatitis C. Semin Pediatr Infect Dis 1997;8:17-22.